FUJIFILM Diosynth Biotechnologies Capacity Update October 2023: Biologics
Michael Dunn, Vice President, Commercial Development and Cristina Brinkmann, Drug Product & Finished Goods Business Steering Group Lead, FUJIFILM Diosynth Biotechnologies, share how FDB is poised to support your molecule’s journey from concept to commercialization.
Michael Dunn presents an update on FDB’s currently available and incoming capacity for the Development and Drug Substance Manufacturing of Biologics, including microbial and cell culture modalities across the CDMO’s global locations in the United States and Europe. Cristina Brinkmann shares the current and future state of FDB’s Drug Product and Finished Goods capabilities to provide their clients full end-to-end CDMO services.
